The bill amends existing laws regarding "Collaborative Pharmacy Practice" to expand the scope of collaborative practice agreements by allowing licensed pharmacists to collaborate not only with physicians but also with other healthcare providers. Key definitions are updated, including the replacement of "physicians" with "providers" in various contexts, and the introduction of a "written agreement" in place of "protocols" for drug therapy management. The bill emphasizes that collaborative practice agreements must adhere to clinical guidelines and standards of care, and it establishes that these agreements can be enacted without prior approval, provided all required documentation is complete.

Additionally, the bill removes the definition of the "collaborative practice committee," which previously consisted of appointed individuals from pharmacy and medical boards. It clarifies that collaborative practice agreements shall be reviewed and signed by the parties annually and that it is the responsibility of the parties to respond to inquiries from the boards regarding the agreements. The bill also includes provisions for immunity for the director of health, board members, and their agents, protecting them from civil or criminal liability for actions taken in good faith during their official duties. The changes are set to take effect on July 1, 2026.